SLC5A2 and dementia: Sodium-glucose co-transporter 2 (SGLT2) inhibitors are now widely used for treating T2DM, especially in people with cardiorenal complications.80 Their use is associated with reduced risk of dementia in people with T2DM; data from the recent nested case-control study by Wium-Andersen et al. indicate that this class of drug actually has neuroprotective effects.81 The study enrolled 176,250 people with T2DM registered in the Danish National Diabetes Register.